Olmix is a marine biotechnology specialist providing algae-based therapeutic solutions in CNS, oncology and immunology.
AN UNIQUE INNOVATIVE SOLUTION
Olmix group has developed specific knowledge and technologies to extract and select algal molecules of interest for animal and plant health. Some of these molecules can also be beneficial for human health and one of them has been identified as a potential antidepressant for humans.
We have found in algae a new antidepressant molecule which from what we know at the moment provide beneficial effects against depression without any undesirable side effect.
KEY VALUE PROPOSITION
- Efficient Natural solution
- No side effect
- Easy to produce
TARGET MARKET SEGMENTS
- Central Nervous system
- Other applications and compounds in oncology and immunology
- Co-development partners with interest in described therapeutic areas
- Investors (Corporate funds, VC...)
Hervé DEMAISScientific Advisor
Your innovative solution
Backed by unique experience acquired through more than 600 clients, including the world
At the core of our innovative connection-based concept, our qualifying approach generates as much information as possible about the pharmacological behavior of a molecule. With this approach, Oncodesign aims to optimally position each molecule towards a disease indication and a patient population, in order to maximize its value.
Pharmaceutical Labs / Biotechs / Academics
Innovation: Oncodesign devises new solutions (Pharmimage)
One Million Solutions in Health
As a not-for-profit, the goal of One Million Solutions in Health is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery ... of innovative cures, treatments and preventative measures for patients around the world.
In this next year, we will be reviewing 100's of new solutions and new scientific discoveries through the Technology Evaluation Consortium™ (contact us about membership). By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way.
We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. As an example, we have had a fabulous, global response, through our sister company, to find cures and raise $100 million to support their commercialization.
We are thrilled to have you be a part of this transformative journey!
Ms Dawn Van DamPresident & CEO
OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company that aims to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development, and commercialization expertise and our novel and proprietary technologies. We intend to leverage our global commercialization expertise to pursue acquisitions of commercial businesses that will both drive our growth and provide geographically diverse sales and distribution opportunities. We have and may continue to make investments in other early stage companies that we perceive to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder.
Our Focus is on Point-of-Care and Novel Molecular Diagnostics, Proprietary Pharmaceuticals, and Vaccines. Since 2009, OPKO has completed five national and international acquisitions contributing to its technology and commercial operations.
OPKO continues to explore acquisition opportunities for complementary pharmaceuticals, compounds, technologies, and businesses. We expect our future growth to arise from leveraging our proprietary technology, development strengths, and pursuit of complementary and strategic acquisitions and investments.
Pharmaceutical and Diagnostic Products, Medical Devices
Phil Frost MDChairman and CEO
Mr Mitch Steiner
OrthoCyte Corporation, a subsidiary of BioTime, Inc., is a biotechnology company developing cell-based therapies for bone and orthopedic soft tissue diseases and injuries. OrthoCyte has a vast library of proprietary normal human progenitor stem cells to skeletal tissues including, bone, articular cartilage, intervertebral disc, tendon, and ligament, all of which are in the preclinical phase of development.MARKET OPPORTUNITY
Many surgical procedures of the spine require bone grafts to regenerate bone that has been removed or damaged due to disease or trauma. OncoCyte is focused on working toward improving patient outcomes in the spinal orthobiologics market which is currently estimated to be over $2 billion annually in the U.S., and is expected to reach $2.7 billion annually by 2020, according to GlobalData.
Dr Francois BinetteVIce President Research and Business Development
Otolaryngology (Ear, Nose, Throat)
Your innovative solution
OsseoMatrix has developed a direct 3D printing process of biological ceramics which enables the manufacturing of patient specific synthetic bone implants
The bioceramic implants developed by OsseoMatrix fit the anatomical complexity of cranio-maxillo-facial or orthopaedic bone losses, resulting of trauma, infection, tumor.
Market 1: Cranio-facial Market 2: Dental Market 3 Orthopaedic 4 Laboratories
advantage 1 less invasive / advantage 2 same composition as bone / advantage 3 patient specific / advantage 4 regenerative